[
    [
        {
            "time": "2018-05-01",
            "original_text": "AbbVie Rises 3%",
            "features": {
                "keywords": [
                    "Rises",
                    "3%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie Rises 3%",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-06-15",
            "original_text": "MC10, Inc. and AbbVie (NYSE:ABBV) Announce Clinical Trials in Multiple Sclerosis Using the BioStamp nPoint® System",
            "features": {
                "keywords": [
                    "Clinical Trials",
                    "Multiple Sclerosis",
                    "BioStamp nPoint®"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "MC10, Inc. and AbbVie (NYSE:ABBV) Announce Clinical Trials in Multiple Sclerosis Using the BioStamp nPoint® System",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-07-10",
            "original_text": "Here are the stocks to buy if an all-out U.S.-China trade war erupts, says Goldman",
            "features": {
                "keywords": [
                    "U.S.-China trade war",
                    "Goldman"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "global trade",
                    "finance"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Here are the stocks to buy if an all-out U.S.-China trade war erupts, says Goldman",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-08-20",
            "original_text": "AbbVie stock up 1.3% after announcing resolution to litigation over Humira in the U.S.",
            "features": {
                "keywords": [
                    "stock up",
                    "litigation",
                    "Humira"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie stock up 1.3% after announcing resolution to litigation over Humira in the U.S.",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-09-12",
            "original_text": "AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim",
            "features": {
                "keywords": [
                    "Resolves",
                    "HUMIRA®",
                    "Patent Litigation",
                    "Boehringer Ingelheim"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-11-14",
            "original_text": "AbbVie to Present at the UBS Global Healthcare Conference",
            "features": {
                "keywords": [
                    "Present",
                    "UBS Global Healthcare Conference"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie to Present at the UBS Global Healthcare Conference",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]